Answers are grounded in this paper and cite their sources.
Cross-sectional study reveals high prevalence of central hypothyroidism in epilepsy patients on antiseizure medications.
Background: Antiseizure medications are the backbone of epilepsy management, but they are often associated with many endocrine and metabolic disturbances. Among the endocrine disturbances, subclinical hypothyroidism is a known entity. However, central hypothyroidism associated with antiseizure medications remains poorly characterized in epilepsy patients. Objectives: To determine the prevalence of central hypothyroidism in persons with epilepsy, to compare the prevalence among older versus newer antiseizure medications, and to identify the individual antiseizure medications strongly associated with central hypothyroidism. Methods: This cross-sectional study evaluated 203 epilepsy patients at Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India. Persons with preexisting thyroid disorders were excluded from the study. Central hypothyroidism was defined as low fT3 (< 4 pmol/L) and/or low fT4 (< 9 pmol/L) with normal or low thyroid-stimulating hormone (TSH) (≤ 5 µIU/mL). Antiseizure medications were categorized into older (e.g., valproate, phenobarbital) and newer (e.g., levetiracetam, zonisamide) generations for comparison. Results: The prevalence of central hypothyroidism in the study was 10.3%, which is strikingly high compared to the estimated general population prevalence of 0.001%. Maximum prevalence of central hypothyroidism was observed with perampanel (33.3%), zonisamide (31.6%), and phenobarbital (25%), while there was no central hypothyroidism observed in patients on lacosamide and brivaracetam. The risk of central hypothyroidism was comparable between older (9.6%) and newer (9.1%) antiseizure medications groups with no statistically significant difference between the two groups. The postulated mechanisms of hypothyroidism due to use of antiseizure medications include blunting of the hypothalamic-pituitary-thyroid axis, competitive bind to thyroid binding globulin, increase peripheral T4-to-T3 conversion, and suppression of thyrotropin-releasing hormone/TSH secretion. Conclusion: Central hypothyroidism is an underdiagnosed complication of antiseizure medications, which needs prompt diagnosis and management due to the high risk of metabolic disturbances and an increased cardiovascular risk. Thus, we recommend routine annual thyroid screening in comprehensive epilepsy care. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Gauri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: